Explore

Trendline Trendline
Brainstorm Cell Therapeutics Reports Narrower Loss in Q1 2026 Amid Clinical Developments

Brainstorm Cell Therapeutics Reports Narrower Loss in Q1 2026 Amid Clinical Developments

Brainstorm Cell Therapeutics Reports Narrower Loss in Q1 2026 Amid Clinical Developments
Trendline Trendline
Marker Therapeutics Reports Improved Financials Amidst Ongoing Clinical Developments

Marker Therapeutics Reports Improved Financials Amidst Ongoing Clinical Developments

Marker Therapeutics Reports Improved Financials Amidst Ongoing Clinical Developments
Trendline Trendline
Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss
Trendline Trendline
Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates

Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates

Spruce Biosciences Reports Q1 2026 Financial Results and Corporate Updates
Trendline Trendline
Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase
Trendline Trendline
NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements

NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements

NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements
Trendline Trendline
Cabaletta Bio Reports Increased Net Loss in Q1 2026 Amid Ongoing Clinical Developments

Cabaletta Bio Reports Increased Net Loss in Q1 2026 Amid Ongoing Clinical Developments

Cabaletta Bio Reports Increased Net Loss in Q1 2026 Amid Ongoing Clinical Developments
Trendline Trendline
Brainstorm Cell Therapeutics Reports Narrowed Loss in Q1 2026 Amid Clinical Developments

Brainstorm Cell Therapeutics Reports Narrowed Loss in Q1 2026 Amid Clinical Developments

Brainstorm Cell Therapeutics Reports Narrowed Loss in Q1 2026 Amid Clinical Developments
Trendline Trendline
Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements

Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements

Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements
Trendline Trendline
NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials

NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials

NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials
Trendline Trendline
Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue

Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue

Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue
Trendline Trendline
Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026

Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026

Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026